Want to see FR:DBV full AI Analyst Report?
DBV Stock Chart & Stats
€3.62
€0.10(13.73%)
At close: 4:00 PM EST
€3.62
€0.10(13.73%)
Day’s Range― - ―
52-Week Range€1.45 - €4.50
Previous CloseN/A
Volume1.76M
Average Volume (3M)1.12M
Market Cap
€831.76M
Enterprise Value€343.87M
Total Cash (Recent Filing)€229.20M
Total Debt (Recent Filing)€6.10M
Price to Earnings (P/E)―
Beta0.41
Next Earnings
Jul 29, 2026EPS Estimate
-0.02Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.97
Shares Outstanding296,061,500
10 Day Avg. Volume2,165,856
30 Day Avg. Volume1,121,838
Financial Highlights & Ratios
PEG Ratio0.53
Price to Book (P/B)3.28
Price to Sales (P/S)0.00
P/FCF Ratio-4.37
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price Target
€3.26Price Target Upside-10.08% Downside
Rating ConsensusHold
Number of Analyst Covering2
EPS Forecast (FY)-0.14
Revenue Forecast (FY)€2.79M
Bulls Say, Bears Say
Bulls Say
Low Leverage / Strong Balance SheetVery low debt and a sizable asset base give DBV durable financial flexibility to fund clinical programs and commercial preparations over the next several months. This reduces refinancing pressure, permits strategic partnering or staged program spending, and lengthens runway versus highly leveraged peers.
Proprietary EPIT Platform (Viaskin)DBV’s Viaskin platform is a structural competitive asset: a novel delivery technology applicable across multiple allergens and indications. If clinical/ regulatory success follows, the platform supports recurring product sales, licensing and partnership revenue streams, and differentiation vs single-drug competitors.
Improving Free Cash Flow TrendAlthough FCF remains negative, the reported improvement in trailing free cash flow indicates management has begun to slow cash burn or reallocate spending. A sustained downward trend in burn is a durable operational improvement that extends runway and reduces near-term funding risk while pivotal programs advance.
Bears Say
Zero TTM Revenue And Large LossesThe company has no recurring product revenue and posts substantial net losses, leaving it dependent on external financing or milestone receipts. Over the medium term this erodes equity, increases dilution risk, and means operational progress must convert to commercial revenues to sustain the business model.
Sustained Negative Operating Cash FlowPersistent material cash burn shows that accounting losses translate into real cash outflows. Even with low debt, repeated negative OCF forces reliance on capital markets or partnerships to fund trials and commercialization, creating execution and dilution risk if funding conditions tighten.
No Margins; Revenue DeclineA complete loss of revenue and nonexistent margins eliminate operational leverage and leave future profitability fully contingent on successful product approvals and market adoption. This structural dependency magnifies binary regulatory/commercial outcomes for medium-term viability.
DBV Technologies News
DBV FAQ
What was DBV Technologies’s price range in the past 12 months?
DBV Technologies lowest stock price was €1.45 and its highest was €4.50 in the past 12 months.
What is DBV Technologies’s market cap?
DBV Technologies’s market cap is €831.76M.
When is DBV Technologies’s upcoming earnings report date?
DBV Technologies’s upcoming earnings report date is Jul 29, 2026 which is in 25 days.
How were DBV Technologies’s earnings last quarter?
DBV Technologies released its earnings results on Apr 30, 2026. The company reported -€0.019 earnings per share for the quarter, beating the consensus estimate of -€0.023 by €0.004.
Is DBV Technologies overvalued?
According to Wall Street analysts DBV Technologies’s price is currently Overvalued.
Does DBV Technologies pay dividends?
DBV Technologies does not currently pay dividends.
What is DBV Technologies’s EPS estimate?
DBV Technologies’s EPS estimate is -0.02.
How many shares outstanding does DBV Technologies have?
DBV Technologies has 296,061,500 shares outstanding.
What happened to DBV Technologies’s price movement after its last earnings report?
DBV Technologies reported an EPS of -€0.019 in its last earnings report, beating expectations of -€0.023. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of DBV Technologies?
Currently, no hedge funds are holding shares in FR:DBV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
DBV Technologies
DBV Technologies S.A. is a clinical-stage biopharmaceutical company focusing on the research and development of epicutaneous immunotherapy products. Its flagship product candidate, Viaskin Peanut, an immunotherapy, has completed Phase III clinical trials and is designed to treat peanut allergies in children aged 4 to 11, as well as adolescents and adults. The company is also advancing Viaskin Milk, which is in Phase I/II clinical trials for Immunoglobulin E (IgE)-mediated cow's milk protein allergy (CMPA). Beyond this, its pipeline includes Viaskin Egg, a preclinical product for hen's egg allergy, and a booster vaccine for Bordetella pertussis. Further early-stage research programs are exploring a vaccine for respiratory syncytial virus, as well as treatments for Crohn's disease, celiac disease, and type I diabetes. DBV is collaborating with Nestlé Health Science on MAG1C, a ready-to-use atopy patch test for diagnosing non-IgE mediated CMPA in infants and toddlers. Founded in 2002, DBV Technologies S.A. is headquartered in Montrouge, France.
DBV Stock 12 Month Forecast
Average Price Target
€3.26
▼(-10.08% Downside)
Technical Analysis
Options Prices
Currently, No data available
---